What's alpha-1 antitrypsin deficiency?
Alpha-1 antitrypsin deficiency is an inherited condition in which a change in the SERPINA1 gene alters a protective blood protein called alpha-1 antitrypsin. The altered protein can build up inside liver cells and, separately, too little of it reaches the lungs, so two organs are affected through opposite problems with the same protein.
| Also indexed as | OMIM:613490, MONDO:0013282 |
|---|---|
| Features mapped | 12 |
| Treatments mapped | 6 |
| Published sources | 16 |
| Last reviewed | 2026-08-04 |
Signs and symptoms
Hepatocellular carcinoma
Long-standing liver damage from the condition can, in some adults, lead to liver cancer (hepatocellular carcinoma).
Elevated circulating hepatic transaminase concentration
When the liver is involved in alpha-1 antitrypsin deficiency, abnormal liver enzyme levels in the blood can be a characteristic sign.
Decreased circulating alpha-1-antitrypsin concentration
A blood test typically shows a low level of alpha-1 antitrypsin, because the protein is held back in the liver instead of circulating.
Chronic bronchitis
COPD is not a single, uniform disease. People with COPD can experience different patterns of illness, such as emphysema, chronic bronchitis, or a combination of both.
Early young adult onset
Lung damage in alpha-1 antitrypsin deficiency can begin earlier in life than usual, including early-onset emphysema in people who have never smoked.
Autosomal recessive inheritance
The condition is inherited from both parents. It is often described as autosomal recessive, meaning the most severe form usually requires two altered copies of the gene, though even one altered copy can carry some risk.
Cirrhosis
In some people the protein trapped in the liver damages it over time, which can progress to scarring (cirrhosis).
Panacinar emphysema
In the lungs, the shortage of alpha-1 antitrypsin leaves an enzyme called neutrophil elastase unchecked, so it gradually breaks down the walls of the air sacs. This loss of protection can lead to a form of emphysema, often appearing earlier in life than usual.
Chronic pulmonary obstruction
Alpha-1 antitrypsin deficiency can lead to airflow obstruction, in which air moves less freely through the lungs, often beginning early in adult life.
Dyspnea
Alpha-1 antitrypsin deficiency can cause dyspnea (shortness of breath), among other symptoms that can resemble asthma.
Cough
Alpha-1 antitrypsin deficiency can cause a cough, among other symptoms that can resemble asthma.
Bronchiectasis
The lung disease in alpha-1 antitrypsin deficiency is not always limited to emphysema. It can also involve bronchiectasis, a condition in which the airways become widened and damaged.
How it is diagnosed
Alpha-1-Antitrypsin deficiency
Diagnosed using: Biopsy.
“Serum level measurement, phenotyping and liver biopsy can be used for establishing the diagnosis.”
Alpha-1-Antitrypsin deficiency
Diagnosed using: serum alpha-1 antitrypsin level.
“Current diagnostic strategies rely on a stepwise approach beginning with serum AAT measurement, followed by phenotyping and genotyping to confirm pathogenic…”
Alpha-1-Antitrypsin deficiency
Diagnosed using: alpha-1 antitrypsin phenotyping (Pi typing).
“Current diagnostic strategies rely on a stepwise approach beginning with serum AAT measurement, followed by phenotyping and genotyping to confirm pathogenic…”
Alpha-1-Antitrypsin deficiency
Diagnosed using: SERPINA1 genotyping.
“…in cases of reduced AAT values, it is recommended to implement automatic alerts suggesting SERPINA1 genotyping using reliable and accessible laboratory…”
Treatment and management
What the research describes, not a recommendation. Treatment decisions belong with your clinician.
This covers treatments that appear in the published research mapped here. Investigational and experimental therapies are not included, so their absence is a boundary of this map, not a sign they do not exist.
augmentation therapy
For the lungs, augmentation therapy infuses alpha-1 antitrypsin purified from donated human plasma to raise blood levels above a protective threshold. It is used for emphysema linked to severe deficiency and does not treat the liver disease.
Used to help with: Alpha-1-Antitrypsin deficiency.
“Augmentation therapy was first approved by the United States Food and Drug Administration (FDA) in 1987 for emphysema associated with severe AATD and today, six augmentation therapy preparations, all of which derive from pooled human plasma, have received FDA approval.”
liver transplantation
Because the altered protein is made in the liver, a liver transplant can effectively correct the condition in people with advanced liver disease by replacing the source of the protein. It is reserved for advanced disease and is not appropriate in early disease.
Used to help with: Alpha-1-Antitrypsin deficiency.
“Alpha-1-antitrypsin (AAT) synthesized in the liver can form damaging polymers that also result in reduced circulating AAT levels and, whilst liver transplantation is used to effectively treat AATD, it is inappropriate in early disease.”
Gene therapy
Gene therapy now uses new methods to edit genes or RNA directly, which are safer than the older approach of simply inserting a replacement gene.
Used to help with: Alpha-1-Antitrypsin deficiency.
“Genome and RNA editing modalities have revolutionized precision gene therapy, offering a safer alternative to traditional gene replacement approaches.”
long-acting bronchodilators
In alpha-1 antitrypsin deficiency, long-acting bronchodilators (medicines that help open the airways) may be used to relieve breathlessness.
Used to help with: Alpha-1-Antitrypsin deficiency.
“Relief of breathlessness may be obtained with long-acting bronchodilators and inhaled…”
lung transplantation
For advanced lung disease in alpha-1 antitrypsin deficiency, transplantation can be an option.
Used to help with: Alpha-1-Antitrypsin deficiency.
“Surgical and interventional approaches, including lung volume reduction techniques and transplantation, provide options for advanced…”
avoidance of risk factors
Managing alpha-1 antitrypsin deficiency includes lifestyle changes and avoiding risk factors that can worsen the disease.
Used to help with: Alpha-1-Antitrypsin deficiency.
“Management emphasizes lifestyle modification, avoidance of risk factors, and pharmacological…”
What changes how it shows up
Carrying the genetic change is not the whole story. The factors below are described in the research mapped here as changing whether, or how strongly, the condition appears. They modulate how the genotype is expressed; they do not, on their own, cause or cure it.
single Z allele
Carrying just one Z copy rather than two is linked to a higher chance of lung or liver problems in some people. Risk is not all-or-nothing, and having the gene change does not by itself mean a person develops disease.
Described as modulating: Alpha-1-Antitrypsin deficiency.
“However, growing evidence suggests that inheritance of a single Z allele increases the risk of disease in some individuals.”
How to read the evidence labels
Where this comes from
This guide is built from 16 published source(s). Every claim above links back to one of them. Click any source ID to read the original on PubMed.
Take it further
Printed, source-linked documents built from this condition's graph — ready to bring to an appointment or attach to a coverage request. Every claim carries its published source, the same as this guide.